
Following a positive recommendation from the European Medicines Agency (EMA), the European Commission has officially approved Ascendis Pharma's Lonapegsomatropin, Ascendis announces in a press release.
Lonapegsomatropin, which is developed under the name Transcon hGH and marketed in the US as Skytrofa, is a once-weekly injection for pediatric patients, and the approval follows a positive opinion from the EMA's expert committee, the CHMP, in November.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app